Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.51 |
| ▸ | CTRC | Q99895 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927837 | 0.83 | F2 (0.57) | F2CTRCF10PRSS2 | |
| SCHEMBL6745950 | 0.80 | F2 (0.64) | F2CTRCPRSS2 | |
| SCHEMBL7650982 | 0.80 | F2 (0.58) | F2CTRCF10PRSS2 | |
| SCHEMBL6750572 | 0.79 | F2 (0.62) | F2CTRCF10PRSS2 | |
| SCHEMBL6749509 | 0.77 | F2 (0.63) | F2CTRCPRSS2 | |
| Hydrochloric Acid SCHEMBL7649325 | 0.77 | F2 (0.55) | F2CTRCF10PRSS2 | |
| SCHEMBL6749192 | 0.76 | F2 (0.64) | F2CTRCF10PRSS2 | |
| SCHEMBL6749564 | 0.72 | F2 (0.66) | F2CTRCPRSS2 | |
| SCHEMBL6747814 | 0.71 | F2 (0.72) | F2CTRCPRSS2 | |
| SCHEMBL6749826 | 0.70 | F2 (0.47) | F2CTRCF10PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | F2 32/4885CTRC 91/4885F10 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.